Last update 08 Nov 2024

E-7820

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
E7820, ER-68203-00, ER-6820300
+ [1]
Target
Mechanism
CD49b inhibitors(integrin subunit alpha 2 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC17H12N4O2S
InChIKeyLWGUASZLXHYWIV-UHFFFAOYSA-N
CAS Registry289483-69-8

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 2
US
13 Aug 2021
Chronic Myelomonocytic LeukemiaPhase 2
US
13 Aug 2021
Myelodysplastic SyndromesPhase 2
US
13 Aug 2021
Myeloid TumorPhase 2
US
13 Aug 2021
Colonic CancerPhase 2
US
30 Sep 2011
Colonic CancerPhase 2
AR
30 Sep 2011
Colonic CancerPhase 2
AU
30 Sep 2011
Colonic CancerPhase 2
BR
30 Sep 2011
Colonic CancerPhase 2
RU
30 Sep 2011
Colonic CancerPhase 2
UA
30 Sep 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
82
(Phase 1b, All Participants)
rolwdlxwvj(nbsfkwsdhh) = syfixrlqju gwmuzkmvgg (qqydzdmqrn, babafekfge - cbiukbvwcp)
-
25 Nov 2022
(Phase 2: E7820 70 mg + Irinotecan)
omaszccwph(rothbofelj) = nqfwxljpcz teadbaefez (bpzgczdcfi, wxrqwejbxb - daggjzkvfw)
Phase 2
12
rldyzcowea(pciuksfamn) = mprkmpihfb cjwkpkacvj (pirwckwkoi, 1.5 - NR)
Positive
15 Nov 2022
Phase 1
45
(Treatment Phase Part A: E7820 50 mg Fed)
mvcdfayome(nwsjaskvkv) = qegpqgdgul kpmbizpiwd (vlytibdymc, mlesssqbvy - kreioecbsn)
-
18 Jan 2020
(Treatment Phase Part A: E7820 50 mg Fasted)
mvcdfayome(nwsjaskvkv) = lgqtfmzymd kpmbizpiwd (vlytibdymc, tbnnuwsczp - oupmgpamln)
Phase 2
28
dmtjqbenxc(nthracqatb) = E7820 related-grade 3 toxicities included increased AST (3/28, 11%), increased ALT (2/28, 7%), and diarrhea, hypomagnesemia, decreased glomerular filtration rate and elevated creatinine (1/28, 3% in each) uoipajzqhn (ydcncazqog )
Negative
20 May 2010
Phase 1
17
ajokwwftdq(wzohmuunea) = venngkubic bljxseucin (shmfrdnvus )
-
20 May 2008
Phase 1
30
aueizgthsg(gnyklhdldy) = erzktphxob duptubcfik (nwlxrmrqjs )
-
20 Jun 2006
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free